TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06045247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Given under the skin
Study: NCT05298423

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pembrolizumab/vibostolimab
Description: Administered as an intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: durvalumab
Description: Administered as an IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: Administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Administered as an IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed
Description: Administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: Administered as an IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: etoposide
Description: Administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Administered as an IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Administered as an IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Administered as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Administered as an IV infusion

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: thoracic radiotherapy
Description: Administered as an external beam radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: thoracic radiotherapy
Description: Administered as an external beam radiation
Study: NCT05275855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDI048
Description: Oral Liquid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDI048
Description: Oral Liquid

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Liquid

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Liquid
Study: NCT05883644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Participants will receive 1500 mg at Day 1 and later receive as monotherapy starting at Week 4 for every 4 weeks through IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Participants will receive single dose of 300 mg through IV infusion at Day 1
Study: NCT06083857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Given by IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib
Description: Given by PO
Study: NCT04777396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semagludtide
Description: Oral semaglutide once-daily, dose gradually increased to 14 mg. The study will last for up to 173 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (semaglutide)
Description: Oral placebo (semaglutide) once-daily, The study will last for up to 173 weeks
Study: NCT05327894

Intervention type: DRUG
Group type: OTHER
Intervention: Blinatumomab
Description: 1st cycle: 15 μg/m2/day as a 4 week continuous IV infusion for patients with a M1 marrow. For patients with a M2/M3 marrow a step-dosing strategy is required with a dose of 5 μg/m2/day in week 1 followed by 15 μg/m2/day in weeks 2, 3, and 4.

Intervention type: DRUG
Group type: OTHER
Intervention: Blinatumomab
Description: 1st cycle: 15 μg/m2/day as a 4 week continuous IV infusion for patients with a M1 marrow. For patients with a M2/M3 marrow a step-dosing strategy is required with a dose of 5 μg/m2/day in week 1 followed by 15 μg/m2/day in weeks 2, 3, and 4.

Intervention type: DRUG
Group type: OTHER
Intervention: Blinatumomab
Description: 2nd cycle: 15 μg/m2/day as a 4 week continuous iv infusion
Study: NCT05075993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LVGN3616 + LVGN6051 + Nab-Paclitaxel
Description: Given by IV, Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LVGN3616 + LVGN6051 + Nab-Paclitaxel
Description: Given by IV, Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LVGN3616 + LVGN6051 + Nab-Paclitaxel
Description: Given by IV, Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LVGN3616 + LVGN6051 + Nab-Paclitaxel
Description: Given by IV, Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide
Description: Given by IV, Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide
Description: Given by IV, Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide
Description: Given by IV, Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide
Description: Given by IV, Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel
Description: Given by IV, Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel
Description: Given by IV, Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel
Description: Given by IV, Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel
Description: Given by IV, Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide
Description: Given by IV, Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide
Description: Given by IV, Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide
Description: Given by IV, Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide
Description: Given by IV, Given by PO
Study: NCT06576063

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumoral Treatment
Description: Home-use of photodynamic antibacterial dual-light device, used with a marker substance (indocyanine green)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard oral hygiene methods
Description: Best available standard oral self-care hygiene methods performed at home and instructed by oral healthcare professionals, supported by professional cleaning at the oral healthcare clinic

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard oral hygiene methods
Description: Best available standard oral self-care hygiene methods performed at home and instructed by oral healthcare professionals, supported by professional cleaning at the oral healthcare clinic
Study: NCT06082063

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin tablet
Description: Antiplatelet treatment: with aspirin 75mg OD is mandatory except for concomitant anticoagulant therapy or allergy. In case of allergy clopidogrel will be used.
Study: NCT05834647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prilocaine 2%
Description: 50 mg prilocaine 2% (2.5 mL volume) before undergoing cystoscopy procedure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric Lidocaine 5%
Description: 50 mg Hyperbaric Lidocaine 5% (1.0 mL volume) before undergoing cystoscopy procedure
Study: NCT04203199

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real rTMS to the mPFC using H7 Coil
Description: This will be delivered with the Brainsway H7 coil system; 1200 pulses with the H7 coil helmet. Blinded using active/sham operator cards.
Study: NCT06082063

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: GLP-1RA treatment: With semaglutide once weekly individually stepped highest tolerable dose according to standard guidelines aiming at 1 mg/week for persons with HbA1c \>53 mmol/mol or BMI\>25 kg/m2 and/or ischemic heart disease and/or stroke. For safety see below under benefits and risks. Investigators should pay attention to the need for adjustment in insulin dose after initiation of GLP-1RA treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sotagliflozin
Description: SGLT2i treatment with sotagliflozin 200 mg once daily for persons with UACR \>30 mg/g and eGFR \< 45 ml/min/1.73 m2 and for persons with a diagnosis of HF. For safety see below under benefits and risks. The limit of eGFR (\<45ml/min) for initiation of SGLT2i treatment is set to reduce risk of ketoacidosis. SGLT2i treatment should not be offered to participants on insulin pump therapy, to reduce risk of ketoacidosis. Investigators should pay attention to the need for adjustment in insulin dose after initiation of SGLT2i treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Finerenone
Description: Finerenone: 10 mg once daily titrated to 20 mg as add-on in persons with persistent albuminuria (\>30 mg/g) despite RAS blockade.
Study: NCT05164094

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1189
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1189
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1189
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1189
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1189
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1189
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1189
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1189
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1189
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1189
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection
Study: NCT05375955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07038124 ointment 0.01%
Description: Atopic Dermatitis and Plaque Psoriasis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07038124 ointment 0.01%
Description: Atopic Dermatitis and Plaque Psoriasis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle ointment
Description: Atopic Dermatitis and Plaque Psoriasis

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle ointment
Description: Atopic Dermatitis and Plaque Psoriasis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07038124 ointment 0.03%
Description: Atopic Dermatitis and Plaque Psoriasis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07038124 ointment 0.03%
Description: Atopic Dermatitis and Plaque Psoriasis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07038124 ointment 0.06%
Description: PF-07038124 ointment 0.06% (Plaque Psoriasis only)
Study: NCT06416111

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIRS
Description: Near Infra-Red Spectroscopy (NIRS) is a non-invasive monitoring modality which measures regional tissue oxygenation defined as percentage (%).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIRS
Description: Near Infra-Red Spectroscopy (NIRS) is a non-invasive monitoring modality which measures regional tissue oxygenation defined as percentage (%).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pinprick Test
Description: With the pinprick test, the practitioner gently touches the skin with the pin and asks the patient whether it feels sharp or blunt .Test begins distally and then move proximally (aiming to test each dermatome and each main nerve).~Assessment of sensorial blockade uses 3 grade system. Grade 0.Sharp pain Grade 1.Analgesia ,numbness Grade 2.Anesthesia ,no feeling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Modified Bromage Scale
Description: Assessment of motor blockade uses 4 point Modified Bromage Score. 0.Normal motor function with full extension and flexion of elbow, wrist and fingers~1. Decreased motor strengths with ability to full flexion elbow and move fingers but inability to raise arm~2. More decreased motor strengths with inability to move elbow but ability to move fingers 3.Complete motor block with inability to move elbow, wrist, and fingers.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Bupivacaine is a potent local anesthetic with unique characteristics from the amide group of local anesthetics.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prilocaine
Description: Prilocaine is an amide local anesthetic secondary amine with an intermediate length of duration and quick onset of action.
Study: NCT05374525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APRETUDE
Description: Available as intramuscular injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APRETUDE
Description: Available as intramuscular injection.
Study: NCT04203199

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real rTMS to the dlPFC using H1 Coil
Description: This will be delivered with the Brainsway H1 coil system; 3000 pulses with the H1 coil helmet. Blinded using active/sham operator cards.
Study: NCT05374525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir OLI
Description: Available as marketed orally administered tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabotegravir OLI
Description: Available as marketed orally administered tablets.
Study: NCT06411288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AOC 1001 (del-desiran)
Description: Del-desiran will be administered by intravenous (IV) infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered by intravenous (IV) infusion.
Study: NCT05136196

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scans

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI scans

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT05576727

Intervention type: OTHER
Intervention: Unruptured intracranial aneurysms
Description: Extensive clinical, biological and imaging data of unruptured intracranial aneurysm patients will be recorded during a 5 years follow-up.
Study: NCT06280950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: * The first step is the addition of everolimus to participants in this group pre-randomization.~* Participants on a mycophenolate compound will stop taking it within 7 days of initiating everolimus, either by immediate discontinuation or a 7-day taper.~* Participants taking prednisone will taper off prednisone by 6 months post-transplant.~* The second step is tacrolimus minimization and withdrawal to everolimus monotherapy in this group after randomization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus (continued reduction)
Description: * Participants randomized in this cohort will have their tacrolimus dose reduced by 50% following randomization.~* They will maintain this daily dose for 4 weeks/1 month (28-30 days). Tacrolimus withdrawal will occur in intervals of 30 days or 4 weeks.~* Each subsequent reduction will be based on LFT stability over the prior time interval before the next reduction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus (maintain 50% reduction)
Description: - Participants randomized in this cohort maintain initial reduced dose of Tacrolimus and everolimus for study duration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: * The first step is the addition of everolimus to participants in the interventional group pre-randomization.~* Participants on a mycophenolate compound will stop taking it within 7 days of initiating everolimus, either by immediate discontinuation or a 7-day taper.~* Participants taking prednisone will taper off prednisone by 6 months post-transplant.~* The second step is to continue on the reduced tacrolimus and everolimus regimen.
Study: NCT06635135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aticaprant
Description: Aticaprant will be administered orally.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally.
Study: NCT06378801

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control Form 1
Description: Participants will use their Placebo Control Form 1 as directed for a period of 6 weeks.
Study: NCT05493696

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Antigravity treadmill
Description: Alter G training for 30-minute, 3 times/week, 75% body weight

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional physical therapy program
Description: applied 3 times/week for 12 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physical therapy program
Description: applied 3 times/week for 12 weeks
Study: NCT06378801

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Relaxation Active Study Product 1.1
Description: Participants will use their Radicle Relaxation Active Study Product 1.1 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control Form 2
Description: Participants will use their Placebo Control Form 2 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Relaxation Active Study Product 2.1
Description: Participants will use their Radicle Relaxation Active Study Product 2.1 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control Form 3
Description: Participants will use their Placebo Control Form 3 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Relaxation Active Study Product 3.1
Description: Participants will use their Radicle Relaxation Active Study Product 3.1 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control Form 4
Description: Participants will use their Placebo Control Form 4 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Relaxation Active Study Product 4.1
Description: Participants will use their Radicle Relaxation Active Study Product 4.1 as directed for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Relaxation Active Study Product 4.2
Description: Participants will use their Radicle Relaxation Active Study Product 4.2 as directed for a period of 6 weeks.
Study: NCT06547268

Intervention type: DEVICE
Intervention: Wireless sensor and platform
Description: Skin-mounted sensor that pairs with tablet platform
Study: NCT05756764

Intervention type: DRUG
Intervention: Semaglutide
Description: Medication for weight loss

Intervention type: DRUG
Intervention: Phentermine-Topiramate combination
Description: Medication for weight loss

Intervention type: DRUG
Intervention: Phentermine
Description: Medication for weight loss

Intervention type: DRUG
Intervention: Tirzepatide
Description: Medication for weight loss

Intervention type: DRUG
Intervention: Topiramate
Description: Medication for weight loss

Intervention type: DRUG
Intervention: Diethylpropion
Description: Medication for weight loss

Intervention type: DRUG
Intervention: Naltrexone/Bupropion
Description: Medication for weight loss
Study: NCT05657548

Intervention type: RADIATION
Intervention: spine and pelvis radiography
Description: X-ray of the spine and pelvis from the front and the side will be performed under the standardized conditions that we put in place: in a sitting position on a specific modular chair.
Study: NCT05722067

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: calcium ionophore
Description: The intervention group will be treated with a ready-to-use ionophore medium (GM508 CultActive, Gynemed) within 15 min after ICSI (or 18 min in IVF) based on the situation of sperm. After 15 min of incubation in GM508 CultActive and a thorough washing process, the oocytes will be cultured in the same protocol as the control group.